fashion -WSS

fashion

author：entertainment 2025-09-28 02:27:31 - browse：2522

Purple AML cells in blood flow — coverage from STAT — Acute myeloid leukemia cells amid blood flow. Adobe

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the use of Carvykti.

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti. That’s partly because physicians already discuss the risk of second cancers due to other cancer therapies including radiation, some targeted therapies, and some chemotherapies, which are necessary in the use of CAR-T. “We do have secondary primary malignancy discussions with patients in the context of transplant and will have to do for CAR-T as well,” Usmani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Surprise medical billing ban raises prices elsewhere

WSS

Congress may force more Covid

CVS is on a mission to consolidate health care. Will it work?

Mass General, Mayo Clinic look to monetize custom

Immunocompromised patients offer clues on chronic Covid

Elevance, SCAN deals highlight health insurer acquisition scrutiny

New CMS data security rules will hurt Medicare, Medicaid research

focus

fashion

entertainment

The high cost of giving birth even with insurance

Reporting on presidential health from Reagan to Trump and Biden

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Obamacare plans could cover weight loss drugs

United colonoscopy coverage change 'may cost lives,' doctors say

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Obamacare plans could cover weight loss drugs

focus

In 'major milestone,' FDA approves first cell therapy for solid tumors

To bolster infectious disease surveillance, genomics powerhouses team up

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

In 'major milestone,' FDA approves first cell therapy for solid tumors

FDA endorses new sterilization method for medical devices

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

hotspot

Wikipedia

entertainment

focus